LWT,
Journal Year:
2023,
Volume and Issue:
187, P. 115361 - 115361
Published: Sept. 1, 2023
Chocolate
is
a
food
product
highly
popular
worldwide,
and
it
has
been
proposed
as
carrier
for
probiotic
delivery.
This
work
evaluated
the
viability
of
strains,
Bifidobacterium
animalis
subsp.
lactis
BB-12®
Akkermansia
muciniphila
DSM
22959,
in
chocolate
matrices
with
different
cocoa
percentages
(33.6;
54.5
70.5%)
throughout
28-days
aerobic
storage.
The
pH,
total
phenolic
content
antioxidant,
antidiabetic,
antihypertensive
activities
were
also
determined
at
timepoints
0
28-days.
During
storage,
all
chocolates
showed
high
pH
stability
(variations
lower
than
1
unit)
was
observed
growing
trend
bioactivities
increase
matrix.
Regarding
viability,
higher
level
B.
achieved
containing
70.5%
(estimated
108
CFU/g
after
storage).
In
opposite,
A
22959
exhibited
greater
33.6%
54.5%
(around
106
meeting
minimum
required
amounts
products).
Conjugating
data
from
physicochemical
properties,
dark
cocoa,
may
be
considered
promising
vector
A.
BB-12®,
respectively.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(10), P. 9087 - 9087
Published: May 22, 2023
Several
studies
in
recent
years
have
demonstrated
that
gut
microbiota-host
interactions
play
an
important
role
human
health
and
disease,
including
inflammatory
cardiovascular
diseases.
Dysbiosis
has
been
linked
to
not
only
well-known
diseases,
such
as
bowel
rheumatoid
arthritis,
systemic
lupus
erythematous,
but
also
risk
factors,
atherosclerosis,
hypertension,
heart
failure,
chronic
kidney
obesity,
type
2
diabetes
mellitus.
The
ways
the
microbiota
is
involved
modulating
are
multiple
related
mechanisms.
Indeed,
microbiome
cooperate
a
metabolically
active
superorganism,
this
affects
host
physiology
through
metabolic
pathways.
In
turn,
congestion
of
splanchnic
circulation
associated
with
edema
intestinal
wall,
altered
function
permeability
barrier
result
translocation
bacteria
their
products
into
circulation,
further
enhancing
pro-inflammatory
conditions
underlying
disorders.
aim
present
review
describe
complex
interplay
between
microbiota,
its
metabolites,
development
evolution
We
discuss
possible
interventions
intended
modulate
reduce
risk.
Virulence,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: Aug. 27, 2024
Metabolic
disease
is
a
worldwide
epidemic
that
has
become
public
health
problem.
Gut
microbiota
considered
to
be
one
of
the
important
factors
maintain
human
by
regulating
host
metabolism.
As
an
abundant
bacterium
in
gut,
Pediatric Cardiology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Aug. 22, 2024
Abstract
The
gut
microbiome
of
infants
with
congenital
heart
disease
(CHD)
undergoing
cardiopulmonary
bypass
surgery
(CPB)
is
at
risk
profound
alteration.
aim
this
study
was
to
examine
the
pre-
and
post-bypass
explore
potential
implications
altered
biodiversity.
A
prospective
cohort
involving
CHD
who
underwent
CPB
performed.
Faecal
samples
were
collected
from
alongside
collection
demographic
clinical
data
in
order
changes
before
after
surgery.
16S
rRNA
sequencing
analysis
performed
on
DNA
isolated
stool
determine
composition.
Thirty-three
patients
recruited,
thirteen
these
available
for
final
analysis.
Compared
healthy,
matched
controls,
a
genus
level,
pre-operative
demonstrated
higher
relative
abundance
Escherichia-Shigella
(31%
vs
2–6%)
lower
Bifidobacterium
(13%
40–60%).
In
post-operative
samples,
(35%),
Enterococcus
(11%),
Akkermansia
(6%),
Staphylococcus
(5%)
than
pre-op
samples.
One
infant
developed
necrotising-enterocolitis
(NEC).
They
displayed
marked
(93%)
pre-operatively.
This
demonstrates
that
have
an
when
compared
healthy
controls
there
might
be
possible
link
between
virulent
species
NEC.
MedComm,
Journal Year:
2025,
Volume and Issue:
6(5)
Published: April 18, 2025
ABSTRACT
Dysbiosis
refers
to
the
disruption
of
gut
microbiota
balance
and
is
pathological
basis
various
diseases.
The
main
pathogenic
mechanisms
include
impaired
intestinal
mucosal
barrier
function,
inflammation
activation,
immune
dysregulation,
metabolic
abnormalities.
These
involve
dysfunctions
in
gut–brain
axis,
gut–liver
others
cause
broader
effects.
Although
association
between
diseases
caused
by
dysbiosis
has
been
extensively
studied,
many
questions
remain
regarding
specific
treatment
strategies.
This
review
begins
examining
causes
summarizes
potential
representative
imbalance.
It
integrates
clinical
evidence
explore
preventive
therapeutic
strategies
targeting
emphasizing
importance
understanding
dysbiosis.
Finally,
we
summarized
development
artificial
intelligence
(AI)
research
suggested
that
it
will
play
a
critical
role
future
studies
on
combining
multiomics
technologies
AI
further
uncover
complex
drive
personalized
Microorganisms,
Journal Year:
2024,
Volume and Issue:
12(11), P. 2246 - 2246
Published: Nov. 6, 2024
Cardiovascular
diseases
(CVDs)
are
a
leading
cause
of
widespread
morbidity
and
mortality.
It
has
been
found
that
the
gut
oral
microbiomes
differ
in
individuals
with
CVDs
compared
to
healthy
individuals.
Patients
often
require
long-term
pharmacological
interventions.
While
these
medications
have
extensively
studied
for
their
cardiovascular
benefits,
emerging
research
indicates
they
may
also
impact
diversity
composition
microbiomes.
However,
our
understanding
how
factors
influence
compositions
remains
limited.
Studies
shown
statins
beta-blockers,
particular,
microbial
dysbiosis,
impacting
metabolism
absorption
medications.
These
alterations
can
lead
variations
drug
responses,
highlighting
need
personalized
treatment
approaches.
The
microbiome's
role
CVD
on
microbiome
crucial
variations.
there
very
few
studies
this
area,
not
all
studied,
emphasizing
necessity
further
conclusively
establish
cause-and-effect
relationships
determine
clinical
significance
interactions.
This
review
will
provide
evidence
patients
interact
specific
drugs
used
treatment.
